Ghent University Academic Bibliography

Add to list

NGS-analysis to the rescue : dual checkpoint inhibition in metastatic osteosarcoma : a case report and review of the literature

Laure Nuytemans (UGent) , Gwen Sys (UGent) , David Creytens (UGent) and Lore Lapeire (UGent)

(2020) ACTA CLINICA BELGICA.

Add to list

Journal Article
open access

Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity

Dmitri Krysko (UGent)

(2020) Journal for ImmunoTherapy of Cancer. 8(2).

Add to list

Journal Article
open access

Angiosarcoma in an arteriovenous fistula after kidney transplantation: Case report and review of treatment options

Paulien Van Acker (UGent) , Nic Veys, Sabrina Speybrouck and Wim Van Biesen (UGent)

(2020) HEMODIALYSIS INTERNATIONAL. 24(4). p.431-438

Add to list

Chimeric antigen receptor T-cell therapy : design improvements and therapeutic strategies in cancer treatment

Steven Van Schandevyl and Tessa Kerre (UGent)

(2020) ACTA CLINICA BELGICA. 75(1). p.26-32

Add to list

Journal Article
A1
open access

Recombinant viruses delivering the necroptosis mediator MLKL induce a potent antitumor immunity in mice

Lien Van Hoecke (UGent) , Stephanie Riederer, Xavier Saelens (UGent) , Gerd Sutter and Juan Jose Rojas

(2020) ONCOIMMUNOLOGY. 9(1).

Add to list

Journal Article
A1
open access

Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy

Azahara Rodriguez-Dominguez, Margot Berings (UGent) , Alexander Rohrbach, Huey-Jy Huang, Mirela Curin, Philippe Gevaert (UGent) , Paolo M. Matricardi, Rudolf Valenta and Susanne Vrtala

(2020) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 146(5). p.1097-1108

Add to list

Journal Article
A1
open access

MAIT cells come to the rescue in cancer immunotherapy?

Zuzanna Łukasik (UGent) , Dirk Elewaut (UGent) and Koen Venken (UGent)

(2020) CANCERS. 12(2).

Add to list

Safety, tolerability, and potential clinical activity of a glucocorticoid-induced TNF receptor-related protein agonist alone or in combination with nivolumab for patients with advanced solid tumors : a phase 1/2a dose-escalation and cohort-expansion clinical trial

Kimberley M Heinhuis, Matteo Carlino, Markus Joerger, Massimo Di Nicola, Tarek Meniawy, Sylvie Rottey (UGent) , Victor Moreno, Anas Gazzah, Jean-Pierre Delord, Luis Paz-Ares, et al.

(2020) JAMA ONCOLOGY. 6(1). p.100-107

Add to list

Journal Article
A1
open access

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR : a multicentre, randomised controlled open-label phase II trial

Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, et al.

(2020) BMC CANCER. 20(1).

Add to list

Journal Article
A1
open access

Intracellular delivery of mRNA in adherent and suspension cells by vapor nanobubble photoporation

Laurens Raes (UGent) , Stephan Stremersch (UGent) , Juan Fraire (UGent) , Toon Brans (UGent) , Glenn Goetgeluk (UGent) , Stijn De Munter (UGent) , Lien Van Hoecke (UGent) , Rein Verbeke (UGent) , Jelter Van Hoeck (UGent) , Ranhua Xiong (UGent) , et al.

(2020) NANO-MICRO LETTERS. 12(1).

Academic Bibliography

NGS-analysis to the rescue : dual checkpoint inhibition in metastatic osteosarcoma : a case report and review of the literature

Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity

Angiosarcoma in an arteriovenous fistula after kidney transplantation: Case report and review of treatment options

Chimeric antigen receptor T-cell therapy : design improvements and therapeutic strategies in cancer treatment

Recombinant viruses delivering the necroptosis mediator MLKL induce a potent antitumor immunity in mice

Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy

MAIT cells come to the rescue in cancer immunotherapy?

Safety, tolerability, and potential clinical activity of a glucocorticoid-induced TNF receptor-related protein agonist alone or in combination with nivolumab for patients with advanced solid tumors : a phase 1/2a dose-escalation and cohort-expansion clinical trial

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR : a multicentre, randomised controlled open-label phase II trial

Intracellular delivery of mRNA in adherent and suspension cells by vapor nanobubble photoporation

Contents

Support

Contact